Ovarian Cysts Market Global Market Projected to Grow Radiantly By 2023 – by Novartis AG, General Electric Company, Merck & Co., Inc., Boston Scientific Corporation, etc
The Americas holds the largest share of the global ovarian cysts market. Increasing prevalence of the disease, rising per capita healthcare expenditure and increasing awareness for the woman health are some of the major drivers of the market growth within the region. In 2015, according to the Centres for Disease Control and Prevention, in the U.S. the total healthcare expenditure accounted for 17.8% of the total gross domestic product (GDP), which accounted for USD 3.2 trillion. Moreover, developed healthcare sector and availability of huge funds research and development boosts the market growth. However, late diagnosis, and lack of awareness may restrain the market growth during the forecast period. North America dominates the Americas ovarian cysts market due the presence of market players such as Quest Diagnostics Incorporated and Medtronic along with the developed economies like the U.S. and Canada within the region. However, South America shows the fastest growth in the market due to the presence of huge opportunities for the development of the market.
Get Sample PDF Illustration @ https://www.marketresearchfuture.com/sample_request/1784
Europe is the second largest ovarian cysts market, which is followed by Asia Pacific. Availability of funds for research, huge patient population, increasing healthcare expenditures, well-developed healthcare sector and government support for research & development are projected to drive the market growth during the forecasted period. Regionally, Europe is divided into Western Europe and Eastern Europe. Western Europe holds the major share of the regional market, which is majorly contributed by Germany, the U.K., and France. However, Eastern Europe is the fastest growing region due to the huge opportunities in the untapped market.
Asia Pacific is the fastest growing region in the global the market due to the presence of a huge patient population, continuously developing economies like India and China, and presence of huge opportunity in the market. Moreover, favorable government policies and increasing healthcare expenditures fuel the market growth within the region.
On the other hand, the Middle East & Africa holds the least share of the global ovarian cysts market due to the presence of poor economy, especially, in the African region. Majority of the market of this region is held by the Middle East due to the well-developed healthcare sector and huge healthcare expenditure by the presence of economies like Kuwait, Saudi Arabia, Dubai, and Qatar.
Global Ovarian cysts Market - Overview
Ovarian cysts are closed, sac-like structures filled with a liquid or semisolid substance within the ovary. These cysts are usually reported in the ovulating females and generally do not cause any medical complication. However, menopausal development of the ovarian cysts is also possible. In such conditions, the risks of ovarian cancer increases.
Ovarian cysts is a condition with high risks for ovarian cancer. Most of these cysts are discovered during a routine pelvic exam. As per a study published by the Journal of Clinical Research in Paediatric Endocrinology in 2017, the frequency of ovarian cysts is about 1.8% in children aged between 5-9 years and 18.8% in those who aged between 10-18 years. Furthermore, it is estimated that with the onset starts from adolescence and as the age increases the frequency of ovarian cysts increases with a ranges between 3.8 %- 31.3%. Such trends in the prevalence of the ovarian cysts are one of the major factors driving the market growth. Moreover, rising healthcare expenditures and increasing awareness about woman health boost the market growth. However, lack of awareness and low per capita healthcare expenditure in the developing countries may restrain the market growth.
Key Players for Global Ovarian Cysts Market
Market Research Future (MRFR) recognizes the following companies as the key players in Ovarian Cysts Market: There are plenty of large and small market players which operate in this market all over the globe.
Pfizer Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (The Middle East & Africa), Quest Diagnostics Incorporated. (U.S.), Novartis AG (Europe), General Electric Company (Europe), Merck & Co., Inc. (U.S.), Boston Scientific Corporation (U.S.), and Medtronic (U.S) and others are some of the prominent players at the forefront of competition in the global ovarian cysts market and are profiled in MRFR Analysis.
Ovarian Cysts Industry Updates
January, 2016 Teva Pharmaceutical Industries Ltd., announced the launch of a generic equivalent of Ortho Tri-Cyclen Lo tablets in the United States. This drug launch will expand Teva’s women’s health drug portfolio for U.S.
Jan, 2013 Lupin receives FDA approval to market generic Lutera Tablets to market a generic version of Watson Laboratories, Inc.'s Lutera 28 Tablets.
Get Complete Access of Report @ https://www.marketresearchfuture.com/reports/ovarian-cysts-market-1784
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Hadapsar, Pune – 411028
Phone: +1 646 845 9312
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ovarian Cysts Market Global Market Projected to Grow Radiantly By 2023 – by Novartis AG, General Electric Company, Merck & Co., Inc., Boston Scientific Corporation, etc here
News-ID: 1602566 • Views: 221
More Releases from Market Research Future
Clinical Trial Management System Market Demand, Industry Share, Size, Applicatio …
Clinical Trial Management System Market Analysis by Type (Enterprise Clinical Trial Management System), Delivery Model (Licensed Enterprise), Component (Service) and End-User (Medical Device Manufacturers), and Regional Competitive Share, Size and Trends, 2018-2023 Market Overview Clinical Trial Management System Market is mostly a software system which helps to plan, prepare, and manage a large amount of clinical trials data that is produced by biotechnological and pharmaceutical companies. Drug research has gained momentum in
Reusable Satellite Launch Vehicle (RSLV) Market 2019-2023 | Report Information b …
Global Reusable Satellite Launch Vehicle Market Report Information by Configuration (Single Stage, Multiple Stage), by Type (Partially Reusable, Fully Reusable), Vehicle Weight (Up to 4,000lbs, 4000-9000lbs, Over 9000lbs), & by Region - Forecast Till 2023 The Reusable satellite launch vehicle market is estimated to witness a CAGR of more than 12% during the forecast period from 2018 to 2023. The key players in the reusable satellite launch vehicle market are Airbus S.A.S
Bakery Enzymes Market Global Research Report and Top Key Players: AB Enzymes Gmb …
Market Overview The increasing demand for bakery products in the food and beverage industry including, bread, cookies, and pastries are raising the demand for bakery enzymes at a global level. Enzymes are an important ingredient used in most bakery products. There are two scenarios regarding the use of enzymes, either the enzymes are used to convert the raw material into the main product, or the enzymes are used as additives to
Commercial Airport Lighting Market 2019-2023 | Worldwide Overview By Technology, …
Global Commercial Airport Lighting Market Research Report: Information by Technology (LED, Non-LED), by Application (Airside Lighting, Terminal Lighting, Landside Lighting), and by Region — Forecast till 2023 Honeywell International Inc., (US), ADB SAFEGATE (US), ABB (Switzerland), vosla GmBH (Germany), Avlite (Australia), Carmanah (Canada), Eaton (Ireland), atg airports limited (UK), Avionics Group (US), and HELLA GmBH & Co. KGaA (Germany) are some of the prominent players profiled in MRFR Analysis and are
More Releases for Ovarian
Polycystic Ovarian Syndrome Treatment Market - Regional Analysis
The organic and inorganic strategies by the market players will boost the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.).
Polycystic Ovarian Syndrome - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Polycystic Ovarian Syndrome - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Ovarian Syndrome - Pipeline Review, H2 2017, provides an overview of the Polycystic Ovarian Syndrome (Women's Health) pipeline landscape. Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms
Ovarian Cancer Drugs Market Report : 2017
Reports And Markets Publish a New Market Research Report On –"Ovarian Cancer Drugs Market Report : 2017" Access Full Report With Table Of Contents @ https://www.reportsandmarkets.com/reports/united-states-ovarian-cancer-drugs-market-report-2017-1541150 In this report, the United States Ovarian Cancer Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United
Ovarian Cancer - Pipeline Review, H1 2017
Report Hive Market Research Released a New Research Report of 2027 pages on Title " Ovarian Cancer - Pipeline Review, H1 2017 "with detailed Analysis, Forecast and Strategies. Ovarian Cancer - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer - Pipeline Review, H1 2017, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape. Ovarian cancer is any cancerous growth that may occur in different
Ovarian Cancer Drug Pipeline Review H1 2017
Pharmaceutical guide Ovarian Cancer - Pipeline Review H1 2017 guide reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. Report also provides an overview of the Ovarian Cancer (Oncology) pipeline landscape. Report provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and
Ovarian Cancer - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Ovarian Cancer - Heat Map and Analysis to its growing collection of premium market research reports. Ovarian Cancer (OC) is the fifth most common malignancy diagnosed in women, and the most common gynecological cancer, with an estimated 225,000 new cases diagnosed globally in 2008. Rates are particularly high in developed countries, and especially in Northern Europe. However, substantial improvements in